Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Sales Force Recruitment Is 80% Complete; Morale Remains High

Executive Summary

Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26

You may also be interested in...



Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York

Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York

Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges

Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share

Related Content

UsernamePublicRestriction

Register

PS043274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel